Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Price Target Raised to $17.00

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) had its price objective hoisted by analysts at TD Cowen from $15.00 to $17.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen‘s price objective indicates a potential upside of 51.60% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Senseonics Holdings, Inc. Common Stock in a research note on Tuesday. Weiss Ratings raised shares of Senseonics Holdings, Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. Stifel Nicolaus restated a “hold” rating and set a $10.00 target price (up from $9.00) on shares of Senseonics Holdings, Inc. Common Stock in a report on Tuesday. Barclays boosted their price target on Senseonics Holdings, Inc. Common Stock from $10.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Finally, Mizuho decreased their price target on Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Senseonics Holdings, Inc. Common Stock has a consensus rating of “Hold” and a consensus target price of $14.00.

Senseonics Holdings, Inc. Common Stock Stock Up 14.4%

SENS traded up $1.41 during midday trading on Tuesday, hitting $11.21. 3,182,110 shares of the company’s stock traded hands, compared to its average volume of 680,478. The company has a debt-to-equity ratio of 0.62, a current ratio of 6.74 and a quick ratio of 6.40. The company has a market cap of $468.75 million, a PE ratio of -5.04 and a beta of 1.04. The stock’s fifty day simple moving average is $9.12 and its 200-day simple moving average is $7.26. Senseonics Holdings, Inc. Common Stock has a one year low of $4.79 and a one year high of $13.98.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last posted its earnings results on Monday, November 9th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.01). Senseonics Holdings, Inc. Common Stock had a negative return on equity of 165.80% and a negative net margin of 225.09%. The business had revenue of $19.56 million during the quarter. As a group, equities analysts anticipate that Senseonics Holdings, Inc. Common Stock will post -2.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Senseonics Holdings, Inc. Common Stock

In other news, Director Douglas Roeder acquired 13,953 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was acquired at an average cost of $8.98 per share, with a total value of $125,297.94. Following the acquisition, the director owned 171,191 shares in the company, valued at approximately $1,537,295.18. This represents a 8.87% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC bought a new position in shares of Senseonics Holdings, Inc. Common Stock in the second quarter worth about $36,000. The Manufacturers Life Insurance Company acquired a new position in shares of Senseonics Holdings, Inc. Common Stock during the 2nd quarter worth about $65,000. State of Wyoming acquired a new position in shares of Senseonics Holdings, Inc. Common Stock during the 2nd quarter worth about $67,000. Kestra Advisory Services LLC bought a new stake in Senseonics Holdings, Inc. Common Stock during the 1st quarter valued at approximately $68,000. Finally, Cetera Investment Advisers bought a new stake in Senseonics Holdings, Inc. Common Stock during the 1st quarter valued at approximately $85,000. Institutional investors own 12.36% of the company’s stock.

Trending Headlines about Senseonics Holdings, Inc. Common Stock

Here are the key news stories impacting Senseonics Holdings, Inc. Common Stock this week:

• Positive Sentiment: Third-quarter revenue rose about 140% year over year to $19.6 million and beat revenue estimates. Senseonics raised its 2026 revenue outlook to $68 million–$70 million, above the prior $62 million–$66 million range and analyst consensus, and increased its full-year gross-margin outlook to above 60%. Senseonics Q3 2026 financial results
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating with a $14 price target, while Raymond James upgraded SENS from Underperform to Market Perform. These moves may bolster confidence in the company’s outlook. HC Wainwright ratings Raymond James ratings
• Neutral Sentiment: Barclays raised its target to $11 from $10 and maintained Equal Weight; Stifel Nicolaus raised its target to $10 from $9 and kept its Hold rating. Both targets remain below the recent share price, tempering the positive analyst news. Barclays ratings Stifel Nicolaus ratings
• Negative Sentiment: Senseonics reported a third-quarter loss of $0.50 per share, slightly wider than the $0.49 loss analysts expected, and wider than the $0.43 loss a year earlier. Zacks Q3 results coverage

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc. is a medical technology company focused on developing and commercializing long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Its CGM technology is designed to measure glucose levels continuously through a small sensor inserted under the skin, with readings transmitted to an external smart transmitter and mobile application. The company’s primary product is the Eversense CGM system. Unlike many conventional CGM systems that use an externally worn sensor, Eversense uses an implantable sensor and a removable, rechargeable transmitter worn over the sensor site.